Blue Fin Capital’s Gilead Sciences GILD Stock Holding History

Blue Fin Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,938	Closed	-$208K	–	123
2018 Q2	$208K	Sell	2,938 -650	-18%	-$45.9K	0.11%	121
2018 Q1	$270K	Sell	3,588 -325	-8%	-$25.8K	0.15%	109
2017 Q4	$280K	Sell	3,913 -2,075	-35%	-$158K	0.16%	114
2017 Q3	$485K	Buy	5,988 +25	+0.4%	+$1.91K	0.3%	79
2017 Q2	$422K	Sell	5,963 -1,250	-17%	-$83.2K	0.27%	87
2017 Q1	$489K	Buy	7,213 +55	+0.8%	+$3.87K	0.3%	84
2016 Q4	$512K	Buy	7,158 +130	+2%	+$9.66K	0.34%	79
2016 Q3	$556K	Sell	7,028 -430	-6%	-$34.9K	0.45%	66
2016 Q2	$622K	Buy	7,458 +85	+1%	+$7.54K	0.52%	62
2016 Q1	$677K	Sell	7,373 -899	-11%	-$81.1K	0.58%	56
2015 Q4	$837K	Buy	8,272 +185	+2%	+$19.3K	0.64%	55
2015 Q3	$794K	Buy	8,087 +1,335	+20%	+$148K	0.62%	53
2015 Q2	$791K	Buy	6,752 +3,502	+108%	+$383K	0.57%	54
2015 Q1	$319K	Buy	+3,250	New	+$330K	0.23%	106

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Blue Fin Capital's GILD Position: Q3 2018 in Review

Blue Fin Capital sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 2,938 shares — an estimated $208K sold.

Blue Fin Capital first reported a position in GILD in Q1 2015 and held it in 14 quarters. The position peaked at $837K in Q4 2015. 1,528 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Blue Fin Capital reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
Blue Fin Capital sold 2,938 Gilead Sciences shares in Q3 2018, an estimated $208K.
Blue Fin Capital first reported a position in Gilead Sciences in Q1 2015 and held it in 14 quarters.
Blue Fin Capital's Gilead Sciences position peaked at $837K in Q4 2015.
1,528 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Blue Fin Capital's 13F filing for Q3 2018, filed 9 Nov 2018.